To help offset the lack of specialty care in Parkinson’s disease, the Parkinson’s Foundation is offering providers who aren’t experts in the progressive neurodegenerative disorder access to the virtual course, “Utilizing Quality Measures to Improve Parkinson’s Care: What Every Neurologist Needs to Know.” The course, which is…
Inhibikase Therapeutics, which is recruiting up to 120 untreated Parkinson’s disease patients across the U.S. to test its oral therapy IkT-148009, announced that its 201 trial program just dosed its first participant. The Phase 2 trial (NCT05424276) is assessing the safety and tolerability of IkT-148009 versus a…
The risk of Parkinson’s disease is increased among people who have been exposed to the chemical trichloroethylene (TCE), according to a new analysis of U.S. military personnel. The study, “Risk of Parkinson Disease Among Service Members at Marine Corps Base Camp Lejeune,” was published in JAMA…
BioVie is exploring a potentially pivotal Phase 3 clinical trial to test its experimental oral therapy NE3107 in people with Parkinson’s disease. “Throughout the past several months, data reported or presented at major medical conferences have established a compelling rationale for further clinical evaluation of NE3107 in Parkinson’s Disease,”…
A new review study found limited evidence that exercise may be beneficial in slowing Parkinson’s disease progression, as assessed by behavioral, neurochemical, and imaging measures. Yet no particular exercise type emerged as superior to the others for Parkinson’s patients, although evidence hinted that a higher intensity training with…
Neuronic has partnered with Santa Clara University in Silicon Valley to develop a research project to study light therapy guided by real-time brain activity. Light therapy, also called photobiomodulation, is painless and noninvasive, and uses light-emitting diodes (LEDs) to deliver near-infrared light that passes through the skin and…
Bacteria in the group Desulfovibrio may promote the disease-driving clumping of alpha-synuclein protein in Parkinson’s disease, a new study done in nematode worms suggests. “Our findings make it possible to screen for the carriers of these harmful Desulfovibrio bacteria. Consequently, they can be targeted by measures to remove these strains…
An inflammatory protein called ASC was found in laboratory models to help accelerate the toxic spread of alpha-synuclein through the brain in Parkinson’s disease, implying that this protein may be a useful disease target, a new study suggests. “Importantly, … the ASC protein presents as a promising target,” the…
Results from a Phase 1 clinical trial testing the experimental vaccine UB-312 in people with Parkinson’s disease are expected this summer, according to the therapy’s developer Vaxxinity. “Vaxxinity remains on track to meet critical milestones in 2023,” Mei Mei Hu, the company’s CEO, said in a press…
Researchers at the University of Rochester Medical Center are hoping to use digital tools, including the smartphone app mPower, to collect more precise and comprehensive long-term data about Parkinson’s disease. The study, called AT-HOME PD2, is supported by a $4.9-million grant from the National Institutes of Neurological…
Get regular updates to your inbox.